SAFEStart+ Community Request for Proposals (RfP) -Malawi

Country- and Community-Led Scale-Up of Integrated EMTCT Services in Malawi 

SAFEStart+ is pleased to invite civil society organisations (CSOs) in Blantyre and Mulanje (Malawi) to apply for funding to support community-driven activities advancing the triple elimination of HIV, hepatitis B, and syphilis, with a focus on elimination of vertical transmission (EVT).  

With support from Unitaid, SAFEStart+ is led by PATH in partnership with the World Hepatitis Alliance and International Community of Women Living with HIV-Eastern Africa (ICWEA).  

Background 

Despite major progress in child survival, nearly five million children die each year before their fifth birthday—many within the first month of life. Vertical transmission of HIV, hepatitis B, and syphilis remains a leading cause of preventable illness and death. 

Triple elimination refers to integrated prevention, testing, diagnosis, and treatment of these three infections to eliminate mother-to-child transmission and reduce wider community transmission. 

Achieving this requires not only strong health systems, but also meaningful community leadership and engagement. Communities play a critical role in: 

  • Identifying barriers to care  
  • Reaching underserved populations  
  • Reducing stigma and discrimination  
  • Improving uptake and acceptability of services  

Purpose of the Call 

This RfP aims to fund CSOs in Blantyre and Mulanje in Malawi to support data collection for a Values & Preferences (V&P) study on integrated EVT services.  

The study will be led by project partners, Kamuzu University of Health Sciences (KUHeS) and PATH Malawi, and will inform the design and implementation of SAFEStart+ programming in Malawi.  

Scope of Work 

Selected CSOs will: 

  • Conduct community sensitisation and mobilisation  
  • Recruit participants for surveys and FGDs  
  • Disseminate surveys within target populations  
  • Support participant identification for FGDs  
  • Participate in data quality checks and reviews  
  • Collaborate closely with Solina on methodology and implementation  

 

Targets 

  • 100 survey participants across both states  
  • 20 FGD participants  

 

Coordination 

  • Work under the leadership of KUHeS and PATH Malawi  
  • Participate in bi-weekly coordination meetings

 

Geographic Focus 

  • Blantyre: Ndirande H/C, Mpemba H/C, Chileka H/C and Queen Elizabeth Central Hospital 
  • Mulanje: Mulanje District Hospital, Chonde H/C, Mimosa H/C, and Mulanje mission 

 

Funding & Duration 

  • Budget ceiling: Up to $10,000 USD per state   
  • Project duration: Up to 4 months   
  • CSOs may apply for one or both districts  
  • Eligibility Criteria 

    Applicants must:  

    • Be a registered NGO/CSO operating in Blantyre and/or Mulanje   
    • Have experience in community engagement and community-based research   
    • Demonstrate capacity to deliver activities relating to triple elimination and manage funds   
    • Have basic financial and organisational management systems   

    Additional Requirements 

    • Ability to comply with reporting and accountability requirements   
    • Willingness to undergo due diligence and compliance checks   
    • Commitment to non-discrimination and ethical practices   

    What We’re Looking For 

    Strong proposals will:  

    • Demonstrate deep community reach and trust   
    • Show experience working with target populations   
    • Present a clear, feasible recruitment strategy   
    • Address HIV, hepatitis B, and syphilis approaches   
  • How to Apply 

    📄 Download the full RfP and budget template
    📩 Submit your application by email to: safestart@worldhepatitisalliance.org   
    📅 Deadline: 10 May 2026 23:59 WAT 

    Questions & Support 

    For any questions regarding this call, please contact: 
    📧 safestart@worldhepatitisalliance.org and Camila.picchio@worldhepatitisalliance.org  

    Commitment to Community Leadership 

    SAFEStart+ places communities at the centre of research and implementation. We strongly encourage applications from organisations rooted in the communities they serve and committed to advancing equitable, inclusive, and people-centred health services. 

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close